Soligenix Inc (NASDAQ:SNGX)

1.26
Delayed Data
As of Jun 22
 -0.04 / -3.08%
Today’s Change
1.25
Today|||52-Week Range
3.70
-43.23%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$14.5M

Company Description

Soligenix, Inc. engages in the development and commercialization of products to treat rare disease. It operates through the BioTherapeutics, and Vaccines/BioDefense segments. The BioTherapeutics segment offers photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Vaccines/BioDefense segment includes active development programs for RiVax, ricin toxin vaccine candidate, OrbeShield, GI acute radiation syndrome therapeutic candidate, and SGX943, melioidosis therapeutic candidate. The company was founded in 1987 and is headquartered Princeton, NJ.

Contact Information

Soligenix, Inc.
29 Emmons Drive
Princeton New Jersey 08540-5919
P:(609) 538-8200
Investor Relations:

Employees

Shareholders

Individual stakeholders9.97%
Other institutional22.22%
Mutual fund holders2.88%

Top Executives

Christopher J. SchaberChairman, President & Chief Executive Officer
Karen R. KrumeichChief Financial officer & Senior Vice President
Oreola DoniniChief Scientific Officer & Senior Vice President
Richard C. StraubeChief Medical Officer & Senior Vice President
Adam T. RumageVP-Regulatory Affairs & Project Management